Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Phase 1

Recruiting

Conditions: Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Decitabine-primed Tandem CD19/CD20 CAR T Cells

Interventions: Biological: Decitabine-primed Tandem CAR19/20 engineered T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-01-06

Last Posted Date: 2024-02-07

Lead Sponsor: Han weidong

Target Recruit Count: 33

Registration Number: NCT04697940

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Interventions: Genetic: ALLO-316
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-01-06

Last Posted Date: 2024-11-01

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 120

Registration Number: NCT04696731

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 7 locations

IS-free Treg HaploHCT

Phase 1

Recruiting

Conditions: Stem Cell Transplant Complications
Graft Vs Host Disease
Myeloid Leukemia, Acute
Myeloid Leukemia in Relapse (Disorder)
Myelodysplastic Syndromes

Interventions: Radiation: Radiation
Drug: Fludarabine
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mesna
Biological: Treg-enriched donor cell
Biological: Unmodified donor T Cell
Procedure: CD34+ Haplo Peripheral Blood Stem Cell

First Posted Date: 2020-12-22

Last Posted Date: 2024-12-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04678401

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-95266
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2020-12-19

Last Posted Date: 2024-01-26

Lead Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Target Recruit Count: 180

Registration Number: NCT04674813

Locations: 🇺🇸
Local Institution - 008, Baltimore, Maryland, United States
🇺🇸
Local Institution - 009, Duarte, California, United States
🇺🇸
Local Institution - 011, New York, New York, United States

and more 7 locations

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: AB-101
Drug: Rituximab
Drug: Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2020-12-17

Last Posted Date: 2024-02-13

Lead Sponsor: Artiva Biotherapeutics, Inc.

Target Recruit Count: 108

Registration Number: NCT04673617

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
UF Health Shands Cancer Hospital, Gainesville, Florida, United States

and more 18 locations

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Phase 1

Active, not recruiting

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: CAR.B7-H3
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-12-17

Last Posted Date: 2025-01-08

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT04670068

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Phase 1

Conditions: Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)

Interventions: Biological: CD19 CAR engineered autologous T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2020-12-04

Last Posted Date: 2021-03-19

Lead Sponsor: Sabz Biomedicals

Target Recruit Count: 22

Registration Number: NCT04653493

Locations: 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷
Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Phase 2

Recruiting

Conditions: AML
ALL
NHL or HL
Inherited Metabolic Disorders
Bone Marrow Failure
HLH
MDS
MPD Withou Myelofibrosis
Hemoglobinopathies

Interventions: Drug: Clofarabine
Drug: Fludarabine
Drug: Busulfan
Drug: Cyclosporine-A
Drug: Mycophenolate Mofetil
Biological: Cord Blood Graft

First Posted Date: 2020-11-25

Last Posted Date: 2024-12-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT04644016

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

NeoTIL in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor, Adult

Interventions: Biological: NeoTIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Radiation: Radiotherapy

First Posted Date: 2020-11-25

Last Posted Date: 2023-10-13

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 42

Registration Number: NCT04643574

Locations: 🇨🇭
centre hospitalier universitaire vaudois (CHUV), Lausanne, Vaud, Switzerland

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
B Cell Non-Hodgkin's Lymphoma
Lymphoma

Interventions: Genetic: CB-010
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-11-20

Last Posted Date: 2024-11-21

Lead Sponsor: Caribou Biosciences, Inc.

Target Recruit Count: 72

Registration Number: NCT04637763

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 32 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy